ArticleIndian journal of anaesthesia2025
Effect of ketamine/esketamine on postoperative delirium and cognitive dysfunctions: A systematic review and meta-analysis of randomised trials.
Article in Indian journal of anaesthesia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Postoperative delirium (POD) and postoperative neurocognitive dysfunction (POND) are common neurological complications after general anaesthesia. This study aimed to evaluate the effect of perioperative ketamine or esketamine on POD and POND. Methods: We systematically searched PubMed, Embase, Web of Science, and the Cochrane Library for randomised controlled trials investigating perioperative use of ketamine or esketamine versus placebo or no treatment. The primary outcomes included the incidence of POD and POND. Secondary outcomes included postoperative nausea and vomiting, pain scores, length of hospital stay, extubation time, and psychological adverse effects. The pooled estimates were quantified using odds ratios (ORs) and 95% confidence intervals (CIs), and between-study variability was quantified by the I² index, and sensitivity, subgroup analyses, and meta-regression were used to explore effect modifiers. Results: Sixteen studies (2536 patients) demonstrated that ketamine significantly reduced POD risk (OR = 0.62, 95% CI: 0.42, 0.92; I² =51%), while seven studies (453 patients) showed no significant effect on POND (OR = 0.41, 95% CI: 0.14, 1.21; I² =74%). (es)ketamine administration was associated with increased psychological adverse effects (OR = 1.72, 95% CI: 1.24, 2.37; I² =0%). Subgroup analyses revealed that esketamine reduced delirium risk (OR = 0.68, 95% CI: 0.47, 0.98), whereas ketamine prevented neurocognitive disorder (OR = 0.35, 95% CI: 0.20, 0.61). No significant differences were observed in secondary outcomes including nausea/vomiting, pain intensity, hospital stay, or extubation time. Conclusion: Perioperative (es)ketamine significantly reduces POD risk but not POND. Subgroup analyses reveal esketamine excels in delirium prevention, while racemic ketamine shows better cognitive protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.